Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes

Diabetes and Metabolism

Volumn 36, Issue 3, 2010, Pages 198-203

  Ringborg, A ^a,b   Lindgren, P ^a,b   Yin, D D ^c   Martinell, M ^d   Stalhammar J ^d  

^a i3 Innovus   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Hyperglycaemia; Insulin treatment; Oral antidiabetic agents; Secondary failure; Sweden; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; SWEDEN; TIME; BLOOD; BODY MASS; DIABETES MELLITUS, TYPE 2; KAPLAN MEIER METHOD; METABOLISM; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIERS ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; KAPLAN-MEIER ESTIMATE;

EID: 77953293394     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.11.006     Document Type: Article

References (25)

1. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 45 (2002) S5-12
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615.
3. World Health Organization (WHO). Diabetes: fact sheet No. 312. World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed: 13 February 2009.
4. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009) 17-30
5. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed: 15 May 2009.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
8. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009;32 (Suppl. 1):S13-S61.
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
10. Hirsch I.B., Bergenstal R.M., Parkin C.G., Wright E., and Buse J.B. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 23 (2005) 78-86
11. Ringborg A., Lindgren P., Martinell M., Yin D.D., Schon S., and Stalhammar J. Prevalence and incidence of type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study. Diabet Med 25 (2008) 1178-1186
12. Ringborg A., Martinell M., Stalhammar J., Yin D.D., and Lindgren P. Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data. Int J Clin Pract 62 (2008) 708-716
13. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
14. Swedish Association of Diabetology. Diagnoskriterier för Diabetes 1998. Swedish Association of Diabetology. Available at: http://www.diabetolognytt.se/nummer3_97/diagnoskriterier.html. Accessed: 26 March 2009.
15. Hoelzel W., Weykamp C., Jeppsson J.O., Miedema K., Barr J.R., Goodall I., et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50 (2004) 166-174
16. Eliasson B., Eeg-Olofsson K., Cederholm J., Nilsson P.M., and Gudbjornsdottir S. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab 33 (2007) 269-276
17. Eurich D.T., Simpson S.H., Majumdar S.R., and Johnson J.A. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 25 (2005) 810-816
18. Donnan P.T., Steinke D.T., Newton R.W., and Morris A.D. Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study. Diabet Med 19 (2002) 606-610
19. Davis T.M., Davis W.A., and Bruce D.G. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Med J Aust 184 (2006) 325-328
20. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371 (2008) 1753-1760
21. Li Y., Xu W., Liao Z., Yao B., Chen X., Huang Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27 (2004) 2597-2602
22. Ilkova H., Glaser B., Tunckale A., Bagriacik N., and Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20 (1997) 1353-1356
23. Eliasson B., Cederholm J., Nilsson P., and Gudbjornsdottir S. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 22 (2005) 1420-1426
24. Farnkvist L.M., and Lundman B.M. Outcomes of diabetes care: a population-based study. Int J Qual Health Care 15 (2003) 301-307
25. Wigertz A., and Westerling R. Measures of prevalence: which healthcare registers are applicable?. Scand J Public Health 29 (2001) 55-62